Using Community Health Nurses and Workers for Home Visits to Pregnant Women to Improve Maternal and New Born Health in Ghana (CHNCHW)

March 7, 2022 updated by: Dr Marion Okoh-Owusu, Ghana Health Services

A Cluster-randomized Controlled Trial on New Community Partnerships Between Community Health Workers (CHWs) and Nurses (CHNs) for Home Visits to Pregnant Women to Increase Skilled Attendant at Birth (SAB) in Rural Ghana

Title: Using Community Health Workers (CHWs) and Nurses (CHNs) to increase Skilled Attendant at Birth (SAB) and improve Maternal and Neonatal Health in Rural Ghana

Background: SAB is a key strategy for improving maternal and new born health since most of the complications occurring at childbirth could be better managed when the delivery is supervised by a doctor, midwife or nurse. The effect of home visits to pregnant women by a CHW/CHN partnership on SAB is yet to be evaluated in a trial in Ghana. This trial will determine the effectiveness of a CHW/CHN home visit intervention to pregnant women on increasing SAB and improving birth outcomes for mothers and their neonates.

Methods: Following ethical approval, we will train CHWs and CHNs to provide a package of health education and support for delivery during three home visits to each pregnant woman. This partnership will be evaluated through a cluster randomized controlled trial in 20 electoral areas in Ellembelle district of Ghana: 10 will be randomized to receive the CHW/CHN partnership intervention and 10 to the control arm (usual care), with a target recruitment of 46-50 women per cluster. The CHWs and CHNs will receive technical and financial support throughout the study.

Data on SAB, maternal utilization of safe practices during pregnancy, breast feeding initiation, exclusive breastfeeding, immunization coverage for mother and new born, maternal deaths and neonatal death rates will be collected. The impact of the CHW/CHN intervention on these indicators will be reported.

Keywords: Community Health Nurse, Community Health Worker, Maternal, New born, Supervised delivery, Post-natal, Effectiveness

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Methods: Assignment of interventions (for controlled trials) Implementation of intervention, Randomization process Randomization of the 20 electoral areas will be done by a statistician. There will be block randomization of clusters depending on the availability of either a Community Health Nurse midwife or a staff midwife within the Electoral area. The block randomization will ensure adequate distribution of intervention and control arms across all the categories of healthcare services available.

Participants will be assigned to intervention or control once informed consent is given, based on their electoral area. All participants in a cluster will be recruited at a health facility located within the electoral area. Participants will not know which group they belong at the time of consent to reduce selection bias. Following random allocation and assignment to either intervention or the control arm, the groups will continue their usual antenatal care of at least four ANC visits as part of the components of Focused Antenatal Care (FANC) services at facility level. Participants will also have access to all on-going health interventions available for all pregnant women. The interventional arm will in addition to their usual care, receive up to three home visits by the CHW/CHN where specific health information will be provided to the woman.

The demographics of women in the two arms will be compared to determine if any differential take-up resulted in unbalanced groups. There may be other consequences of differential take-up that are not evidenced by a comparison of participant demographics; this will be a limitation of the research but cannot be further mitigated.

Sample size In calculating the sample size, the weighted average of the baseline SAB rate of 37% from 2017 actual data for four health sub-districts and the intra-cluster correlation of 0.033, reported from three studies by Pagel et al in 2011 were used.

Hence for each of the two arms, there will be 10 electoral areas (clusters) in which 46-50 women will be recruited for a total sample size of 456 per arm. The total sample size of 912 mothers means the trial would have 80% power to detect a relative increase of 35% in the rate of SAB with an alpha of 0.05.

The study aims to recruit 46-50 women per cluster. Should no women drop-out of the study, the sample size required to detect the size of effect sought with enough statistical power would be 912 (46-50 per cluster).

Blinding The data collectors will be blinded; they would not know which women were in the intervention or control arms. All data on the primary outcome will be verified by the researcher, who cannot be blinded. Also, it is impossible to blind the pregnant women and the CHW/CHNs.

Involvement of District staff The CHWs and CHNs will conduct the visits; one visit in the second trimester and two in the third trimester- a total of three home visits per pregnant woman. The district officers will assist in supervising the CHW and CHN visits. Other staff who will be blinded, will be trained to collect outcomes data.

Methods: Data collection, management, and analysis Data collection methods Initial data on participants' background characteristics will be documented at the health facility where recruitment occurs. This will be done by the researcher using a pre-tested data collection questionnaire (see Appendix 2) and assisted by midwives. Outcome data will be collected from the pregnant women at the end of the trial by blinded district officers for reliability and validity. This will be done using a questionnaire administered in the woman's home. The blinded data collection officers will collect outcomes data only. They will not know which group the women belong to but the researcher (who will only collect data to verify the primary outcome and visit acceptability) will.

The data collectors will be trained to respond appropriately in circumstances where mother experienced a distressful event during pregnancy and /or delivery (offering empathy and adapting the data collection process intended to avoid any further distress) and contact the researcher immediately. The researcher will then ensure the social welfare officer is linked with the affected woman and her family and the needed support provided.

Data Quality All deliveries will be verified by the researcher at the facility or place where the birth occurred. Also, antenatal visits will be verified from the Maternal health record book.

Data entries, coding, storage Data will be collected on paper by blinded data collection officers. The hard copies will be submitted to the researcher at the end of each day's field work and stored in locked file cabinets at the research unit of the district health directorate. Entries will be made in MS Excel by the researcher. The Excel database (which will be anonymous) will be updated to the Warwick email regularly and Supervisors copied. The hard copies or anonymous soft copies will be made available to the DMEC for data verification. Check codes using Excel formulae will be built into the database to help prevent data entry errors and data loss. The entered datasets will be validated by an independent statistician.

Statistical analyses Statistical tables will be generated, and appropriate statistical tests used to analyze the variables of interest. Data analyses will be done using STATA version 14.0. Dr Nicholas Parsons and Dr Peter Kimani have provided professional statistics support and, have agreed to provide further support with the Randomization process through the school's Statistics Clinic.

The main measure of association to be determined is the Odds Ratios of SAB (OR) in intervention arm compared to control. The estimated effect of the intervention will be presented as OR together with its 95% confidence interval. Same will be computed for the controls. The ORs will be adjusted for clustering . The analysis for each outcome will be by intention-to-treat and will account for clustering by Electoral area.

Description of subject involved The participants involved are pregnant women. Only women who reside in Ellembelle will be enrolled in the study. As such women should have lived continuously in the Electoral area for at least 3 months prior to enrolment into this study. Enrolment will proceed for eligible participants only after informed consent has been given.

Trial monitoring The Trial Steering Committee (TSC) The TSC has seven members comprising, the investigator, the research supervisors who are experienced researchers at the University of Warwick, and four independent policy makers and research experts from the Ghana Health Service and Ghana's Ministry of Health. They will provide technical guidance on the conduct of the trial and support timely and efficient dissemination of findings.

The members of the TSC are

  1. Dr Marion Okoh-Owusu (Researcher) Contact details: +233206301994; Email: m.okoh-owusu@warwick.ac.uk
  2. Dr Celia Brown (Research Supervisor- Warwick) Contact: celiataylor@warwick.ac.uk
  3. Prof Paramjit Gill (Research Supervisor- Warwick)
  4. Dr Abraham Hogson M.D, PHD (Research Division- Ghana)
  5. Dr Alberta Biritwum-Nyarko MD, MPH, MGCP (Ghana Health Service)
  6. Dr Emmanuel Odame MD, MPH, MGCP, (Ministry of Health, Ghana)
  7. The Senior Biostatistician, Ghana Health Service

Data Monitoring and Ethics Committee (DMEC) The trial data will be monitored by the DMEC, which comprises three independent members from Ghana and supported by project supervisors.

DMEC members are:

  1. Mr Isaac Korankye- Snr. Biostatistician (Ghana Health Service)
  2. Mr Francis Nuoh- Snr. Biostatistician, Ghana Health Service
  3. Mr Prince Oppong-Darko - (Health Information Officer)
  4. Dr Celia Brown (Research Supervisor- Warwick)
  5. Prof Paramjit Gill (Research Supervisor- Warwick)

The DMEC will receive confidential data on the trial, monitor progress and give the relevant advice where needed. The CHW/CHN trial is a health education intervention delivered in the pregnant woman's home at the community level, and its evaluation depend on skilled births occurring within a year, hence the DMEC will not conduct any interim analyses.

Study Type

Interventional

Enrollment (Actual)

952

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Western North Region
      • Bodi, Western North Region, Ghana, 00233
        • Western North Regional Health Directorate

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 49 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • All pregnant women age 15-49 years
  • Presenting from 14 to 24 weeks of gestation
  • The woman has completed 13 weeks of gestation
  • The woman resides in the electoral area
  • Resided continuously for three months prior to the start of the study

Exclusion Criteria:

  • Pregnant women who have existing complications
  • Woman requiring the care of a specialist
  • Known previous Medical or Surgical history

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Arm

Study group 1 - Home visits by a team made up of a CHW and CHN in addition to all existing usual care practices (see below).

Standardized educational Messages will be given during these scheduled home visits by the CHW-CHN including:

  • One visit during the second trimester of the pregnancy
  • Two visits during the third trimester of pregnancy
An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 20 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
Other Names:
  • Follow up home visits
No Intervention: Control Arm
Study group 2 (Control) - Existing usual care practices. Usual Care includes at least four antenatal visits and care package which includes education on pregnancy, labour and delivery given at the health facility or at community settings to individuals and/or groups of pregnant women.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of women having Skilled Attendant at Birth
Time Frame: 12 months
Numerator: Total number of deliveries with a Skilled Attendant at Birth Denominator: Total number of live births per arm
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
- Proportion of pregnant women making the fourth antenatal visit
Time Frame: 12 months
Numerator: Total number of pregnant women making the fourth antenatal visit Denominator: Total number of participants per group
12 months
The breastfeeding initiation coverage within 1 hour after delivery among intervention and control arms
Time Frame: 12 months
Numerator: Total number of neonates breastfed within 1 hour of delivery Denominator: Total number of live births per group
12 months
Proportion of women using Insecticide Treated Net (ITN) during pregnancy
Time Frame: 12 months
Numerator: Total number of women who ever used an ITN during pregnancy Denominator: Total number of participants per group
12 months
Proportion of exclusively breastfed neonates at month 1
Time Frame: 12 months
Numerator: Total number of neonates exclusively breastfed at month 1 Denominator: Total number of live births per group
12 months
Maternal Mortality Rate
Time Frame: 12 months
Numerator: Total number of maternal deaths Denominator: Total number of live births per group
12 months
Neonatal Mortality Rate
Time Frame: 12 months
Numerator: Total number of neonatal deaths Denominator: Total number of live births per group
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Celia Brown, PHD, University of Warwick
  • Study Director: Paramjit Gill, MD. PHD, University of Warwick
  • Study Director: Abraham Hodgson, MD. PHD, Ghana Health Services
  • Principal Investigator: Marion Okoh-Owusu, MD. MPH, University of Warwick

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

December 31, 2020

Study Completion (Actual)

December 31, 2020

Study Registration Dates

First Submitted

April 5, 2019

First Submitted That Met QC Criteria

April 5, 2019

First Posted (Actual)

April 8, 2019

Study Record Updates

Last Update Posted (Actual)

March 22, 2022

Last Update Submitted That Met QC Criteria

March 7, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • GHS-ERC: 010/08/18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnant Women

Clinical Trials on Home visits

3
Subscribe